Management of vasoocclusive pain events in sickle cell disease

Pediatric Emergency Care

Volumn 23, Issue 11, 2007, Pages 832-841

  Ellison, Angela M ^a   Shaw, Kathy ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Sickle cell disease; Vasoocclusive pain event

Indexed keywords

ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; CHOLINE MAGNESIUM TRISALICYLATE; CODEINE; HYDROMORPHONE; HYDROXYUREA; IBUPROFEN; KETOROLAC; LAXATIVE; MORPHINE; NAPROXEN; OXYCODONE; PARACETAMOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ANALGESIA; BLOOD TRANSFUSION; BREATHING EXERCISE; CRYOTHERAPY; CYTOPENIA; HUMAN; HYDRATION; HYPERTHERMIC THERAPY; HYPNOSIS; MASSAGE; MORBIDITY; NEUTROPENIA; OXYGEN THERAPY; PAIN; REVIEW; SICKLE CELL ANEMIA; THROMBOCYTOPENIA; VASOOCCLUSIVE PAIN;

ANALGESICS; ANEMIA, SICKLE CELL; ANOXIA; ARTERIAL OCCLUSIVE DISEASES; BLOOD FLOW VELOCITY; EMERGENCY SERVICE, HOSPITAL; ERYTHROCYTE AGGREGATION; ERYTHROCYTES, ABNORMAL; HUMANS; PAIN; PAIN MEASUREMENT; REGIONAL BLOOD FLOW;

EID: 36348959032     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/PEC.0b013e31815a05e2     Document Type: Review

References (42)

1. American Academy of Pediatrics. Health supervision for children with sickle cell disease. Pediatrics. 2002;109(3):526-535.
2. Steinberg MH. Management of sickle cell disease. N Eng J Med. 1999;340(13):1021-1030.
3. Serjeant GR, Ceulaer CD, Lethbridge R, et al. The painful crisis of homozygous sickle cell disease: clinical features. Br J Haematol. 1994;87(3):586-591.
4. Embury SH, Hebbel RP, Mohandas N, eds. Sickle Cell Disease. Basic Principles and Clinical Picture. New York: Raven Press; 1994.
5. Brittain HA, Eckman JR, Swerlick RA, et al. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion. Blood. 1993;81:2137-2143.
6. Hofstra TC, Kalra VK, Meiselman JH, et al. Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst. Blood. 1996;87:4440-4447.
7. Sugihara K, Sugihara T, Mohandas N, et al. Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells. Blood. 1992;80:2634-2642.
8. Wick TM, Moake JL, Udden MM, et al. Unusually large von Willebrand factor multimers preferentially promote young sickle and nonsickle erythrocyte adhesion to endothelial cells. Am J Hematol. 1993;42:284-292.
9. Gee BE, Platt OS. Sickle reticulocytes adhere to VCAM-1. Blood. 1995;85:268-274.
10. Dias-Da-Motta PM, Arruda VR, Muscara MN, et al. The release of nitric oxide and superoxide anion by neutrophils and mononuclear cells from patients with sickle cell anemia. Br J Haematol. 1996;93:333-340.
11. Vichinsky EP, Lubin BH. Sickle cell anemia and related hemoglobin-opathies. Pediatr Clin North Am. 1980;27:429-447.
12. Shapiro BS. The management of pain in sickle cell disease. Pediatr Clin North Am. 1989;36:1029-1045.
13. Rees DC, Olujohungbe AD, Parker NE, et al. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol. 2003;120:744-752.
14. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease: rates and risk factors. N Engl J Med. 1991;325:11-16.
15. Yaster M, Kost-Byerly S, Maxwell LG. The management of pain in sickle cell disease. Pediatr Clin N Am. 2000;47(3):699-710.
16. Rather SJ, Athanasian EA. Water sports and sickle cell anemia. Ann Intern Med. 1986;105:971.
17. Serjeant GR. Sickle Cell Disease. 3rd ed. New York: Oxford University Press; 2001.
18. Ballas S. Pain Management of Sickle Cell Disease. Hematol Oncol Clin N Am. 2005;19:785-802.
19. Fixler J, Syles L. Sickle cell disease. Pediatr Clin North Am. 2002;49(3):1193-1210.
20. Miller ST, Syles L, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342(2):83-89.
21. Benjamin LJ, Dampier CD, Jacox AK, et al. Guideline for the management of acute and chronic pain in sickle-cell disease. Glenview, IL: APS; 1999. APS Clinical Practice Guidelines Series No. 1.
22. National Institute of Health, National Heart, Lung, and Blood Institute, and Division of Blood Diseases and Resources. The management of sickle cell disease. Bethesda, MD: NIH; 2002. NIH publication 02-2117.
23. Shannon M, Berde CB. Pharmacologic management of pain in children and adolescents. Pediatr Clin North Am. 1989;36(4):855-871.
24. Hardwick WE, Givens TG, Monroe KW, et al. Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. Pediatr Emerg Care. 1999;15(3):179-182.
25. Beiter JL, Simon HK, Chambliss R, et al. Intravenous ketorolac in the emergency department management of sickle cell pain and predictors of its effectiveness. Arch Pediatr Adolesc Med. 2001;155:496-500.
26. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med. 1994;330(11):733-737.
27. Rogers ZR, Dale JC, Bernini JC, et al. Dexamethasone shortens the duration of painful events requiring hospitalization in children with sickle cell disease: results of a randomized, double-blind, placebocontrolled trial. Blood. 1996;88:250a.
28. Yaster M, Deshpande JK. Management of pediatric pain with opioid analgesics. J Pediatr. 1988;113:421-429.
29. Shapiro BS, Cohen DE, Howe CJ. Patient-controlled analgesia for sickle-cell-related pain. J Pain Symptom Manage. 1993;8(1):22-28.
30. Schechter NL, Berrien FB, Katz SM. The use of patient-controlled analgesia in adolescents with sickle cell pain crisis: a preliminary report. J Pain Symptom Manage. 1988;3(2):109-113.
31. Trentadue NO, Kachoyeanos MK, Lea G. A comparison of two regimens of patient-controlled analgesia for children with sickle cell disease. J Pediatr Nurs. 1998;13:15-19.
32. Gonzalez ER, Bahal N, Hansen LA, et al. Intermittent injection vs patient-controlled analgesia for sickle cell crisis pain. Comparisons in patients in the emergency department. Arch Intern Med. 1991;151(7):1373-1378.
33. Quinn CT, Buchanan GR. The acute chest syndrome of sickle cell disease. J Pediatr. 1999;135(4):416-422.
34. Sprinkle RH, Cole T, Smith S, et al. Acute chest syndrome in children with sickle cell disease. Am J Pediatr Hemotol Oncol. 1986;8:105-110.
35. Crain SM, Shen KF. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate tolerance/dependence liability. Pain. 2000;84:121-131.
36. Claster S, Vichinsky EP. Managing sickle cell disease. BMJ. 2003;327:1151-1155.
37. Bellet PS, Kalinyak K, Shukla R, et al. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med. 1995;333:699-703.
38. Zipursky A, Robieux I, Brown EJ, et al. Oxygen therapy in sickle cell disease. Am J Pediatr Hemtol Oncol. 1992;14(3):222-228.
39. Robieux IC, Kellner JD, Coppes MJ, et al. Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. Pediatr Hemtol Oncol. 1992;9(4):317-326.
40. Ware MA, Hambleton I, Ochaya I, et al. Day care management of sickle cell pain crisis in Jamaica: a model applicable elsewhere? Br J Haematol. 1999;104:93-96.
41. Benjamin LJ, Swinson GI, Nagel RL. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crisis in SCD. Blood. 2000;95:1130-1136.
42. Ballas SK, Carlos TM, Dampier C, et al. Guidelines for standard of care of acute painful episodes in patients with sickle cell disease. Harrisburg, PA: Pennsylvania Department of Health; 2000.